Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

Infectious Disease Unit 2 > Antiretroviral Drugs > Flashcards

Antiretroviral Drugs Flashcards

1
Q

What are the different stages of the HIV lifecycle where drugs can be used?

A
  1. Binding of the virus to the host cell membrane- blocked by CCR5 receptor antagonists
  2. Fusion and uncoating of the virus- blocked by fusion inhibitors
  3. Reverse transcription- blocked by NRTIs and NNRTIs inhibitors
  4. Viral DNA integration- blocked by integrase inhibitors
  5. Budding and maturation of the virus- blocked by protease and maturation inhibitors
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Maximally suppressive antiretroviral therapy

A

Requires combo of at least 3 drugs

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

What does a typical treatment regimen for HIV look like?

A

“Backbone” – typically 2 NRTIs

“Base” – NNRTI, protease inhibitor, integrase strand transfer inhibitor, CCR5 antagonist

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Selection Criteria for Drugs within a Class

A

Results of resistance testing (treatment-naïve vs -experienced)

Allergy history (screening for presence of HLA*5701)

Hypersensitivity to abacavir

Pregnancy status (efavirenz pregnancy category D)

Patient convenience (once-daily dosing and combo products reduce “pill burden”)

Comorbidities: hepatitis B, tuberculosis, cardiovascular disease, osteoporosis, psychiatric disorders, kidney disease

Side effect profiles

Potential drug interactions: many HAART drugs are CYP450 substrates and/or inducers- inhibitors

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Specific drug combos used

A

Backbone: 2 NRTIs
Tenofovir-Emtricitabine preferred

Base: plus

An integrase inhibitor (Dolutegravir)

or a boosted (+ ritonavir) PI combination (Atazanavir or Darunavir preferred)

or an NNRTI (Efavirenz preferred

or a CCR5 antagonist (Maraviroc)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

NRTIs- Mechanism of action

A

Nucleoside–tide Reverse Transcriptase Inhibitors (Tenofovir disoproxil fumarate, Emtricitabine)

Activation by intracellular kinases to active triphosphate (REQUIRES ACTIVATION)

Phosphorylated analogs competitively inhibit viral RT and when incorporated into viral DNA causes chain termination

Prevents genome replication and establishment of provirus

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

How does HIV develop resistance to NRTIs?

A

Associated with mutations at various AA positions on RT

Cross resistance within class is common and is basis for avoiding certain NRTI combinations

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

What’s important when considering NRTI plasma concentration?

A

plasma levels falling too low: risk of resistance

too high- risk of toxicity

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Which NRTIs are hepatically metabolized and which are renally excreted?

A

Know organ of elimination: avoid DDIs – dosage changes

Hepatic glucuronidation: Abacavir and Zidovudine

Renal excretion: All Others

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Adverse Drug Reactions of NRTIs

A

Class Effects:

Related to varying levels of NRTI activity against mitochondrial DNA polymerase γ: anemia, myopathy, granulocytopenia, neuropathy

Lactic acidosis – hepatic steatosis, potentially fatal

Renal impairment potential with tenofovir

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

What are the two best-tolerated NRTIs?

A

Lamivudine (3TC) and emtricitabine (FTC)

Both agents are also active against HBV in co-infected patients

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

What are the pros and cons of dual NRTI therapy?

A

Advantages:

Established backbone of combination therapy
Minimal drug interactions

Disadvantages:

Lactic acidosis and hepatic steatosis: highest with d4T, then ddI and ZDV, lower with TDF, ABC, 3TC, and FTC (rarely used now)

Lipodystrophy: highest with d4T

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

NNRTIs- Mechanism of action

A

Non-Nucleoside Reverse Transcriptase Inhibitors (Efavirenz)

Possess variety of dissimilar structures

Do NOT require activation by intracellular kinases

Bind to NON-CATALYTIC hydrophobic region and non-competitively inhibit HIV Reverse Transcriptase

Prevents genome replication - establishment of provirus

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

How does HIV develop resistance to NNRTIs?

A

Associated with single AA substitutions at various positions on RT

Developing resistance to one NNRTI confers cross-resistance to remaining class members

Newer member etravirine appears to have higher barrier to resistance

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

DDIs of NNRTIs

A

All are substrates of CYP450: innumerable DDIs due to induction-inhibition of CYP450 and potential for altered levels of co-administered PIs

Efavirenz: induces CYP3A4 (decreased methadone levels)

Etravirine: induces CYP3A4 – inhibits CYP2C9-19

Nevirapine: induces CYP3A4

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Efavirenz (what is it and side effects)

A

NNRTI

Most common are rash, dizziness, headache, insomnia, impaired concentration; more severe CNS effects possible

Only anti-retroviral agent in pregnancy category D

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Emtricitabine

A

NRTI

18
Q

Tenofovir disoproxil fumarate

A

NRTI

Hard on pts with kidney disease

19
Q

Pros and cons of NNRTIs

A

Advantages:

Long half-lives
Less metabolic toxicity than PIs
PIs and INSTIs preserved for future use

Disadvantages:

Low genetic barrier to resistance - single mutation
Cross resistance among most NNRTIs
Rash, hepatotoxicity (esp. nevirapine)
Potential CYP450 drug interactions
Transmitted resistance to NNRTIs more common than resistance to PIs

20
Q

PIs- Mechanism of action

A

Protease Inhibitors (Atazanavir, Darunavir)

Noncleavable peptidomimetic agents that selectively target retroviral aspartyl proteases (not host proteases)

HIV protease cleaves and processes HIV gag and pol proteins necessary for survival and replication, thus inhibition prevents viral maturation

21
Q

How does HIV develop resistance to protease inhibitors?

A

Drug resistance to most PIs requires multiple mutations - seldom develops “boosted” PI-based regimens

Relatively high barrier to resistance compared with NNRTIs and integrase inhibitor

22
Q

Atazanavir

A

PI

dosed once daily

less adverse effects on lipid profiles; reversible jaundice; mild-moderate rash (20%)

23
Q

Darunavir

A

PI

dosed once daily

incidence of side effects similar to other PIs, but rash can be severe (S-J Syndrome)

24
Q

DDIs of PIs

A

Metabolized by CYP3A4 and innumerable DDIs occur due to inhibition of CYP3A4

25
Q

Side effects of PIs

A

Many PIs can cause GI distress, hyperglycemia, insulin resistance, hyperilipidemia and increased risk of CAD

Can see peripheral lipoatrophy - central fat accumulation

Hepatotoxicity more common in patients with HBV-HCV

26
Q

Pros and Cons of PIs as part of initial therapy

A

Advantages:

Higher genetic barrier to resistance
PI resistance uncommon even with sub-optimal adherence (boosted PI)
NNRTIs and INSTIs preserved for future use

Disadvantages:

Metabolic complications (fat maldistribution, insulin resistance, dyslipidemia)
GI intolerance
Potential for CYP450 drug interactions (esp. ritonavir)
27
Q

INSTIs- mechanism of action

A

Integrase Strand Transfer Inhibitors (Raltegravir, Dolutegravir)

Viral integrase involved in processing of DNA strands and catalyzing direct insertion of viral DNA into host cell DNA

Raltegravir inhibits integrase activity preventing HIV-1 replication

No effect on human DNA polymerases α, β, or γ

28
Q

Dolutegravir

A

INSTI

unlikely to develop resistance mutations

Eliminated via phase 2 glucuronidation – levels decreased by inducers (e.g., rifampin)

once daily

29
Q

Raltegravir

A

INSTI

eliminated via phase 2 glucuronidation – levels decreased by inducers (e.g., rifampin)

Twice daily

30
Q

HIV resistance to INSTIs?

A

Raltegravir and elvitegravir have low genetic barrier

Dolutegravir unlikely to develop resistance mutations: high barrier

31
Q

Adverse Drug Reactions of INSTIs

A

Generally well tolerated

Diarrhea, nausea, headache

32
Q

Pros and cons of INSTIs as part of initial HIV therapy

A

Advantages:

Neutral effects on triglycerides and cholesterol
High barrier for resistance with dolutegravir
Fewer adverse events than efavirenz
Fewer drug interactions than with NNRTIs or PIs
NNRTIs and PIs preserved for future use

Disadvantages:

Twice daily dosing (once a day for dolutegravir)
Lower genetic barrier to resistance than PIs (RAL-EVG)
Myopathy, rhabdomyolysis, and skin reactions reported but rare

33
Q

Maraviroc

A

Entry Inhibitor

HIV-1 virions using CCR5 called “R5 tropic”, present during initial and chronic phases

HIV-1 virions using CXCR4 called “X4 tropic”, associated with later stages and disease progression

Maraviroc is small molecule antagonist of CCR5 receptor that inhibits its interaction with viral gp120

Indicated for treatment experienced adults with R5-tropic virus (assay to determine R5, X4, or dual tropism)

Dosed twice daily

Substrate of CYP3A4 – DDIs possible with strong CYP3A4 inducers or inhibitors (e.g., NNRTIs or DDIs)

34
Q

Resistance to maraviroc

A

Has been observed, esp. when X4 strains are present; also associated with mutations in viral gp120

35
Q

Adverse rxn to maraviroc

A

Generally well tolerated, mild effects include cough, fever, URI, dizziness, abdominal pain

Hepatotoxicity possible with higher doses

36
Q

Pros and cons of maraviroc in initial HIV therapy

A

Advantages:

Virologic response noninferior to efavirenz
Fewer adverse events than efavirenz
NNRTIs, PIs, and IIs preserved for future use

Disadvantages:

Requires tropism testing before use (CCR5 vs CXCR4)
Twice daily dosing
Less experience than with PI- or NNRTI-based ART - limited data with NRTIs other than ZDV-3TC
CYP3A4 substrate - dosage adjustment required with concomitant inducers or inhibitors

37
Q

Enfuvirtide

A

Fusion Inhibitor

Enfuvirtide is a synthetic peptidomimetic of the viral gp41 HR2 sequences

Binds to HR1 sequences - unavailable for hemiperfusion stalk

Prevention of viral entry into cell and infection

MUST BE ADMINISTERED SUBCUTANEOUSLY

38
Q

Resistance to enfuvirtide

A

Reported to result from mutations in gp41 binding regions

39
Q

DDIs with enfuvirtide

A

Eliminated by proteolytic hydrolysis – no CYP involvement, thus NO potential for DDIs

40
Q

Adverse Drug Reactions of Enfuvirtide

A

Injection site reactions occur in almost all patients

Eosinophilia

Hypersensitivity reactions

Increase in bacterial pneumonia

41
Q

“FOVIR”

A

nucleotides

Infectious Disease Unit 2 (22 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions